LOGIN  |  REGISTER
Terns Pharmaceuticals

SomaLogic to Participate in the Jefferies Healthcare Conference

BOULDER, Colo., May 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming Jefferies Healthcare Conference.

SomaLogic management is scheduled to participate in a fireside chat on Wednesday, June 7, 2023, at 3:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the virtual session on the “Investors” section of the company’s website at: https://investors.somalogic.com/events-and-presentations.

About SomaLogic

SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

SomaLogic Contact
Emilia Costales
720-798-5054
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Contact
Marissa Bych
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page